Incyte Corporation (INCY) : 10 brokerage houses believe that Incyte Corporation (INCY) is a Strong Buy at current levels. 2 Analyst considers the fundamentals to be worthy of a Buy recommendation. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Incyte Corporation (INCY). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 13 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.27.
Incyte Corporation (INCY) : The most positive equity analysts on Incyte Corporation (INCY) expects the shares to touch $135, whereas, the least positive believes that the stock will trade at $90 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $100.82 with an expected fluctuation of $12.47 from the mean.
Shares of Incyte Corporation appreciated by 5.19% during the last five trading days but lost 5.24% on a 4-week basis. Incyte Corporation is up 0.78% in the last 3-month period. Year-to-Date the stock performance stands at -24.48%. Incyte Corporation (NASDAQ:INCY): On Tuesdays trading session , Opening price of the stock was $82.73 with an intraday high of $83.25. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $80.48. However, the stock managed to close at $81.9, a loss of 0.10% for the day. On the previous day, the stock had closed at $81.98. The total traded volume of the day was 1,256,692 shares.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f